Clinical trials
Completed Phase 1 Blast Crisis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
84 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 5 |
| 2001 | 5 |
| 2002 | 4 |
| 2003 | 6 |
| 2004 | 11 |
| 2005 | 6 |
| 2006 | 7 |
| 2007 | 4 |
| 2008 | 2 |
| 2009 | 4 |
| 2010 | 2 |
| 2011 | 1 |
| 2016 | 1 |
| 2017 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 84 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 25 |
| Memorial Sloan Kettering Cancer Center | 5 |
| M.D. Anderson Cancer Center | 4 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 4 |
| Case Comprehensive Cancer Center | 3 |
| Northwestern University | 3 |
| Vion Pharmaceuticals | 3 |
| Virginia Commonwealth University | 3 |
| Indiana University | 2 |
| Roswell Park Cancer Institute | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Blast Crisis | 84 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 77 |
| Leukemia, Myeloid, Acute | 70 |
| Leukemia | 51 |
| Leukemia, Myeloid, Accelerated Phase | 46 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 38 |
| Leukemia, Myelomonocytic, Chronic | 37 |
| Leukemia, Myeloid, Chronic-Phase | 35 |
| Myelodysplastic Syndromes | 32 |
| Burkitt Lymphoma | 30 |
Trials
Showing 1 to 25 of 84. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.